Aloxi® (palonosetron hydrochloride) Injection is a potent, highly selective 5-HT3 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). Approved by the U.S. Food and Drug Administration (FDA) on July 25, 2003 and commercially launched in September 2003, Aloxi is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of both acute and delayed CINV caused by moderately emetogenic chemotherapy.
An oral Aloxi capsule is currently in a phase 3 trial for the prevention of CINV. By developing an oral formulation of Aloxi , MGI PHARMA hopes to offer patients and their caregivers a choice between intravenous and oral formulations that may both provide protection from acute and delayed CINV.
About Chemotherapy Induced Nausea and Vomiting
Chemotherapy induced nausea and vomiting is a common side effect experienced by many cancer patients who are receiving chemotherapy. If not prevented, approximately 70%-80% of all cancer patients receiving chemotherapy may experience CINV. CINV can result in delay of chemotherapy or even discontinuation of treatment. The market in the United States for 5-HT3 receptor antagonists used for the prevention of CINV approximates $1 billion annually.
Patients and health care providers seeking information regarding clinical trials may call MGI PHARMA toll-free at 1-800-562-5580 and press 1 to access our Medical Communications Help Line.